Tagrisso 80 MG tablet 30S
Ended Awarded Last action
- Contract number
- SPE2DR26F1AF4
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,438
Award facts
- Contract value 100% obligated
- $12,438.15 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
This delivery order, valued at $12,438.15 with a firm fixed price structure, awards AmerisourceBergen Drug Corp (a subsidiary of Cencora, Inc.) the supply of Tagrisso 80 mg tablets in quantities of 30 units for the Defense Logistics Agency. The award was made on January 20, 2026, with an ultimate completion date of February 10, 2026, and represents a non-set-aside, competitively awarded contract. Performance will occur at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, a $999,999,999 global pharmaceutical support vehicle that runs through December 2026, enabling the company to supply an extensive range of brand-name and generic medications, vaccines, and medical supplies to support military healthcare programs worldwide.
Tagrisso (osimertinib) is an oncology medication used in the treatment of non-small cell lung cancer, consistent with AmerisourceBergen's established role as a critical pharmaceutical distributor for federal medical procurement. The Defense Logistics Agency's Medical Supply Chain regularly issues such delivery orders through its prime vendor contracts to ensure timely availability of essential medications across military treatment facilities and other federal healthcare systems. AmerisourceBergen's consistent receipt of competitive awards and its substantial indefinite delivery contract with DLA Troop Support Medical underscore the company's capability to meet federal pharmaceutical supply requirements efficiently across multiple therapeutic domains.
Quick answers
Who was awarded contract SPE2DR26F1AF4?
SPE2DR26F1AF4 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 20, 2026.
How much is contract SPE2DR26F1AF4 worth?
The government has obligated $12,438 on SPE2DR26F1AF4.
Is contract SPE2DR26F1AF4 an order under another contract?
Yes. SPE2DR26F1AF4 is a delivery order under SPE2DR25D1205, an indefinite delivery contract.
Was contract SPE2DR26F1AF4 competed?
The extent of competition for SPE2DR26F1AF4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award